Compare EVAX & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVAX | CNF |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | Denmark | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 27.2M |
| IPO Year | 2020 | 2018 |
| Metric | EVAX | CNF |
|---|---|---|
| Price | $3.78 | $3.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 31.5K | 5.5K |
| Earning Date | 05-07-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $252.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $0.37 |
| 52 Week High | $12.15 | $24.00 |
| Indicator | EVAX | CNF |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 26.38 |
| Support Level | $2.45 | $2.85 |
| Resistance Level | $4.64 | $5.31 |
| Average True Range (ATR) | 0.34 | 0.27 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 54.81 | 6.13 |
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.